The safety of extended-release drug formulations for the treatment of ADHD

References

• Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56(3):345–365.
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69(12):1295–1303.
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45(2):192–202.
   PubMed Web of Science ®Google Scholar
• Caye A, Spadini AV, Karam RG, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry. 2016;25:1151–1159.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct. 2005;1(1):2.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211–216.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356–367.
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Gosden J, et al. Amphetamine, past and present – a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–496.
   PubMed Web of Science ®Google Scholar
• Strattera (atomoxetine) CAPSULES for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021411s046lbl.pdf [cited 26 Mar 2017].
   Google Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711.
   PubMed Web of Science ®Google Scholar
• KAPVAY (clonidine hydrochloride) extended-release tablets. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022331s013lbl.pdf. [cited 26 Mar 2017].
   Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–179.
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–165.
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896–1901.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353–364.
   PubMed Web of Science ®Google Scholar
• Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–260.
   PubMed Web of Science ®Google Scholar
• Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34(12):678–694.
   PubMedGoogle Scholar
• Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–763.
   PubMed Web of Science ®Google Scholar
• Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50–62.
   PubMedGoogle Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6):E105.
   PubMed Web of Science ®Google Scholar
• Raman SR, Marshall SW, Gaynes BN, et al. An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom. Psychiatr Serv. 2015;66(6):617–624.
   PubMed Web of Science ®Google Scholar
• Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin. 2011;27(Suppl 2):13–22.
   PubMed Web of Science ®Google Scholar
• Top 25 Psychiatric Medication Prescriptions for 2013. Available from: https://psychcentral.com/lib/top-25-psychiatric-medication-prescriptions-for-2013/[cited 26 Mar 2017].
   Google Scholar
• GoodRX. Available from: https://www.goodrx.com/. [cited 26 Mar 2017].
   Google Scholar
• Childress AC, Sallee FR. Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Drugs Today (Barc). 2012;48(3):207–217.
   PubMed Web of Science ®Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53(2):153–173.
   PubMed Web of Science ®Google Scholar
• Intuniv® (guanfacine) extended-release tablets, for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf. [cited 26 Mar 2017].
   Google Scholar
• Approval letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21411ltr.pdf. [cited 26 Mar 2017].
   Google Scholar
• Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010;122(5):35–41.
   PubMed Web of Science ®Google Scholar
• Cassidy TA, Varughese S, Russo L, et al. Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18-49: a national internet survey. J Atten Disord. 2015;19(7):630–640.
   PubMed Web of Science ®Google Scholar
• Polaha J, Dalton WT 3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106–1112.
   PubMed Web of Science ®Google Scholar
• QUILLIVANT™ XR (methylphenidate hydrochloride) for extended-release oral suspension. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s006lbl.pdf. [cited 26 Mar 2017].
   Google Scholar
• DYANAVEL XR (amphetamine) extended-release oral suspension, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208147s000lbl.pdf. [cited 26 Mar 2017].
   Google Scholar
• QUILLICHEW ER™ (methylphenidate hydrochloride) extended-release chewable tablets, for oral use, CII. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf. [cited 26 Mar 2017].
   Google Scholar
• ADZENYS XR-ODT (amphetamine extended-release orally disintegrating tablets), CII. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204326s002lbl.pdf. [cited 26 Mar 2017]
   Google Scholar
• Sikes C, Addock S, Stark J, et al. Alcohol does not alter the pharmacokinetics and plasma concentrations of a novel extended-release orally disintegrating tablet formulation of amphetamine for treatment of patients with ADHD. Presented at the Annual Meeting of the American Professional society of ADHD and Related Disorders in Washington, DC January 15-17, 2016 2016.
   Google Scholar
• Palladone Pain Drug Pulled Off the Market. Available from: http://www.webmd.com/pain-management/news/20050714/palladone-pain-drug-pulled-off-market#1. [cited 26 Mar 2017].
   Google Scholar
• Cai B, Engqvist H, Bredenberg S. Evaluation of the resistance of a geopolymer-based drug delivery system to tampering. Int J Pharm. 2014;465(1–2):169–174.
   PubMed Web of Science ®Google Scholar
• Vyvanse® (lisdexamfetamine dimesylate) capsules for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021977s039lbl.pdf. [cited 26 Mar 2017]
   Google Scholar
• CONCERTA® (methylphenidate HCl) Extended-Release Tablets, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf. [cited 26 Mar 2017].
   Google Scholar
• ADDERALL XR® (mixed salts of a single-entity amphetamine product) dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulfate capsules, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021303s032lbl.pdf. [cited 26 Mar 2017]
   Google Scholar
• FOCALIN XR (dexmethylphenidate hydrochloride) extended-release capsules CII for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf. [cited 26 Mar 2017]
   Google Scholar
• Wilens J, McBurett K, Stein M. ADHD treatment with once-daily OROS methylphenidate final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1015–1023.
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13(7):614–620.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215–226.
   PubMed Web of Science ®Google Scholar
• Bostrom S, Yoon M, Wang C, et al. Long-term safety and efficacy of clonidine extended-release tablet monotherapy or combination therapy in pediatric patients with ADHD. 164th Annual Meeting of the American Psychiatric Association. Honolulu, HI 2011.
   Google Scholar
• Findling R, Wigal S, Bukstein O, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Cli Ther. 2009;31(8):1844–1855.
   PubMed Web of Science ®Google Scholar
• Adler LA, Orman C, Starr HL, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011;31(1):108–114.
   PubMed Web of Science ®Google Scholar
• Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2009;14(10):573–585.
   PubMed Web of Science ®Google Scholar
• Biederman J, Spencer TJ, Wilens TE, et al. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):16–25.
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer T, McGough JJ, et al. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord. 2009;12(5):449–459.
   PubMed Web of Science ®Google Scholar
• Aptensio XRTM (methylphenidate hydrochloride extended-release) capsules for oral use, CII. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205831s003lbl.pdf. [cited 26 Mar 2017] Rhodes Pharmaceuticals L.P., Coventry, RI (2015).
   Google Scholar
• Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(2):199–208.
   PubMed Web of Science ®Google Scholar
• Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18(3):248–256.
   PubMed Web of Science ®Google Scholar
• Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs. 2008;22(8):693–704.
   PubMed Web of Science ®Google Scholar
• Silva R, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull. 2008;41(1):19–33.
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Muniz R, Ball RR, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):817–823.
   PubMed Web of Science ®Google Scholar
• Childress AC, Spencer T, Lopez F, et al. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(4):351–361.
   PubMed Web of Science ®Google Scholar
• Awudu GA, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update. Drug Saf. 2014;37(9):661–676.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829–835.
   PubMed Web of Science ®Google Scholar
• Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr. 2009;155(1):84–9, 9 e1.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–639.
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395–405.
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373.
   PubMed Web of Science ®Google Scholar
• Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. 2010;50(9):1001–1010.
   PubMed Web of Science ®Google Scholar
• Findling RL, Cutler AJ, Saylor K, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(1):11–21.
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Harpin V, Huss M, et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57(6):717–728.
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–84.
   PubMed Web of Science ®Google Scholar
• Kisicki JC, Fiske K, Phase LA. I, Double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther. 2007;29(9):1967–1979.
   PubMed Web of Science ®Google Scholar
• Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther. 2012;29(5):385–400.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–13.
   PubMed Web of Science ®Google Scholar
• Gregory AM, Agnew-Blais JC, Matthews T, et al. ADHD and sleep quality: longitudinal analyses from childhood to early adulthood in a twin cohort. J Clin Child Adolesc Psychol. 2017 Mar–Apr;46(2):284–294. doi:10.1080/15374416.2016.1183499. Epub 2016 Aug 2.
   PubMed Web of Science ®Google Scholar
• Velez-Galarraga R, Guillen-Grima F, Crespo-Eguilaz N, et al. Prevalence of sleep disorders and their relationship with core symptoms of inattention and hyperactivity in children with attention-deficit/hyperactivity disorder. Eur J Paediatr Neurol. 2016 Nov;20(6):925–937. doi:10.1016/j.ejpn.2016.07.004. Epub 2016 Jul 14.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380–1387.
   PubMed Web of Science ®Google Scholar
• Becker SP, Froehlich TE, Epstein JN. Effects of methylphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder. J Dev Behav Pediatr. 2016;37(5):395–404.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009;12(4):308–315.
   PubMed Web of Science ®Google Scholar
• Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581–588.
   PubMed Web of Science ®Google Scholar
• Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–463.
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman D, Weisler R, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct. 2009;5:34.
   PubMed Web of Science ®Google Scholar
• Giblin JM, Strobel AL. Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. J Atten Disord. 2011;15(6):491–498.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Lopez FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(2):111–120.
   PubMed Web of Science ®Google Scholar
• Warshaw EM, Squires L, Li Y, et al. Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. Prim Care Companion J Clin Psychiatry. 2010;12:6.
   Google Scholar
• DAYTRANA® (methylphenidate transdermal system). HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021514s025lbl.pdf. [cited 01 Apr 2017]
   Google Scholar
• Spencer TJ, Faraone SV, Biederman J, et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45(5):527–537.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1138–1147.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer TJ, Kollins SH, et al. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2010;49(1):24–32.
   PubMed Web of Science ®Google Scholar
• Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54(9):728–736.
   PubMed Web of Science ®Google Scholar
• Crane EH Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. The CBHSQ Report. Rockville (MD) 2013.
   Google Scholar
• Kaland ME, Klein-Schwartz W. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. Clin Toxicol (Phila). 2015;53(5):477–485.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol. 2007;47(12):1476–1488.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–418.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419–427.
   PubMed Web of Science ®Google Scholar
• Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111.
   PubMedGoogle Scholar
• Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol. 2005;32(1):1–10.
   PubMed Web of Science ®Google Scholar
• McAfee AT, Landon J, Jones M, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. Pharmacoepidemiol Drug Saf. 2013;22(4):386–393.
   PubMed Web of Science ®Google Scholar
• Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol. 2013;23(6):534–541.
   PubMed Web of Science ®Google Scholar
• Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis. 2009;52(1):6–10.
   PubMed Web of Science ®Google Scholar
• Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012;169(2):178–185.
   PubMed Web of Science ®Google Scholar
• Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Jama. 2011;306(24):2673–2683. .
   PubMed Web of Science ®Google Scholar
• McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089–1096.
   PubMed Web of Science ®Google Scholar
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904.
   PubMed Web of Science ®Google Scholar
• Childress A, Desousa NJ, Incledon B, et al. The single dose pharmacokinetics of hld200: a modified release methylphenidate (mph) formulation in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Poster presented at the American Professional Society of ADHD and Related Disorders Annual Meeting 2015.
   Google Scholar
• Quinn D, Bode T, Desousa NJ, et al. A phase 2 pharmacokinetics study of a modified release formulation of dextroamphetamine following evening administrations to adolescents and children with ADHD. Poster presented at the American Psychiatric Association Annual Meeting, Toronto, Canada. 2015.
   Google Scholar
• Wigal SB, Wigal T, Childress A, et al. The time course of effect of multilayer-release methylphenidate hydrochloride capsules: a randomized, double-blind study of adults with ADHD in a simulated adult workplace environment. J Atten Disord. 2016 Oct 17. pii: 1087054716672335. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437–1448.
   PubMed Web of Science ®Google Scholar
• Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74.
   PubMed Web of Science ®Google Scholar
• Noven announces positive phase 2 results of investigational d-amphetamine transdermal system For ADHD. Available from http://www.noven.com/PR072213.php. [cited 02 Apr 2017].
   Google Scholar
• Neurovance announces positive centanafadine phase 2b results for adult ADHD, and plans for phase 3 trials. Available from: http://www.neurovance.com/wp-content/uploads/2016/07/Press_Release-Neurovance_CTN_072716_Final_en.pdf. [cited: 02 Apr 2017].
   Google Scholar
• Manor I, Newcorn JH, Faraone SV, et al. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med. 2013;125(4):181–190.
   PubMed Web of Science ®Google Scholar
• Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015;40(12):2745–2752.
   PubMed Web of Science ®Google Scholar
• Fornai F, Grazia Alessandri M, Bonuccelli U, et al. Effect of metadoxine on striatal dopamine levels in C57 black mice. J Pharm Pharmacol. 1993;45(5):476–478.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Golembiowska K, Kowalska M, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012;66(6):522–532.
   PubMed Web of Science ®Google Scholar
• Supernus announces positive results from phase IIb clinical trial for SPN-812 in children with ADHD. Available from: http://ir.supernus.com/releasedetail.cfm?ReleaseID=992959. [cited 12 Mar 2017].
   Google Scholar
• Jones G, Dejesus-Rosario N, Kao C, et al. Exploratory dose-escalation study of NFC-1 in ADHD adolescents with glutamatergic gene network variants. Poster presented at the American Academy of Child and Adolescent Psychiatry 62nd Annual Meeting 2015.
   Google Scholar
• Connolly JJ, Glessner JT, Elia J, et al. ADHD & pharmacotherapy: past, present and future: a review of the changing landscape of drug therapy for attention deficit hyperactivity disorder. Ther Innov Regul Sci. 2015;49(5):632–642. .
   PubMed Web of Science ®Google Scholar
• American adults surpass children in taking drugs to stay focused. Available from: https://www.bloomberg.com/news/articles/2015-06-22/american-adults-surpass-children-in-taking-drugs-to-stay-focused. [cited 02 Apr 2017].
   Google Scholar